TCRX TScan Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TCRX

Price (delayed)

$0.364

Market cap

$24.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.91

Enterprise value

$10.38M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 31
Highlights
The EPS has increased by 17% YoY and by 5% QoQ
The company's net income rose by 14% YoY and by 5% QoQ
TCRX's gross profit is down by 22% from the previous quarter but it is up by 2.2% YoY
TScan Therapeutics's revenue has decreased by 22% QoQ but it has increased by 2.2% YoY
The equity has plunged by 61% YoY and by 29% from the previous quarter
TScan Therapeutics's quick ratio has shrunk by 52% YoY and by 49% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.tscan.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of TCRX

TCRX stock price

How has the TScan Therapeutics stock price performed over time
Intraday
2.59%
1 week
9.97%
1 month
-53.3%
1 year
-79.78%
YTD
-63.6%
QTD
-62.86%

Financial performance

How have TScan Therapeutics's revenue and profit performed over time
Revenue
$7.11M
Gross profit
$7.11M
Operating income
-$120.54M
Net income
-$117.71M
Gross margin
100%
Net margin
-1,655.4%
TCRX's gross profit is down by 22% from the previous quarter but it is up by 2.2% YoY
TScan Therapeutics's revenue has decreased by 22% QoQ but it has increased by 2.2% YoY
TScan Therapeutics's net margin has decreased by 22% QoQ but it has increased by 16% YoY
The operating margin has decreased by 20% from the previous quarter but it has increased by 18% YoY

Price vs fundamentals

How does TCRX's price correlate with its fundamentals

Growth

What is TScan Therapeutics's growth rate over time

Valuation

What is TScan Therapeutics stock price valuation
P/E
N/A
P/B
0.34
P/S
6.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.46
The EPS has increased by 17% YoY and by 5% QoQ
The price to book (P/B) is 62% lower than the 5-year quarterly average of 0.9 and 51% lower than the last 4 quarters average of 0.7
The equity has plunged by 61% YoY and by 29% from the previous quarter
The price to sales (P/S) is 75% lower than the 5-year quarterly average of 25.9 and 64% lower than the last 4 quarters average of 18.2
TScan Therapeutics's revenue has decreased by 22% QoQ but it has increased by 2.2% YoY

Efficiency

How efficient is TScan Therapeutics business performance
TScan Therapeutics's ROE has plunged by 70% YoY and by 18% from the previous quarter
TScan Therapeutics's ROIC has decreased by 44% YoY and by 5% from the previous quarter
The company's return on assets fell by 35% YoY and by 9% QoQ
The ROS has decreased by 21% QoQ but it has increased by 16% YoY

Dividends

What is TCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TCRX.

Financial health

How did TScan Therapeutics financials performed over time
The total assets is 67% greater than the total liabilities
TCRX's current ratio has dropped by 52% year-on-year and by 49% since the previous quarter
TScan Therapeutics's quick ratio has shrunk by 52% YoY and by 49% QoQ
TScan Therapeutics's debt is 32% higher than its equity
The debt to equity has soared by 140% year-on-year and by 39% since the previous quarter
The equity has plunged by 61% YoY and by 29% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.